IP Library Granted Patent US 12,576,218
Granted Patent B2
US 12,576,218 · App. 17/601,928 · Granted Mar 17, 2026

Valve

Inventors: Frank Bartels (Hattingen, DE); Juergen Rawert (Cologne, DE)
Assignee: INVOX BELGIUM NV
A61M11/007A61M15/0065B05B11/026B05B11/1091A61M2202/0468A61M2205/0216
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,576,218
App. No.
17/601,928
Granted
Mar 17, 2026
Kind
B2
Abstract

A valve for an inhalation device for generation of an aerosol of a medically active liquid may include: a housing, inside this housing a reservoir for storing medically active liquid, downstream from this reservoir a pumping unit for generation of a pressure connected to a means for the delivery of mechanical energy to said pumping unit, and downstream said pumping unit a nozzle; wherein the pumping unit includes a hollow cylindrical part and a piston, the cylindrical part having an interior space configured to receive an end portion of said piston, wherein said cylindrical part and said piston are linearly moveable relative to one another such as to form a pumping chamber having a variable volume.

Claims (25)

1 . An inhalation device for generating an aerosol of a medically active liquid and for the inhalative administration of the aerosol of said medically active liquid, said inhalation device comprising:

a housing;

a reservoir within the housing for storing said medically active liquid;

a pumping unit, downstream from the reservoir, for generation of a pressure and connected to a spring; and

a nozzle downstream from the pumping unit; wherein the pumping unit comprises a hollow cylindrical part and a piston, the hollow cylindrical part having an interior space configured to receive an end portion of said piston, wherein said hollow cylindrical part and said piston are linearly moveable relative to one another such as to form a pumping chamber having a variable volume; and

a check valve configured to allow liquid flow in a downstream direction and prevent liquid flow in an opposite direction, the check valve comprising a moveable body and a seat arranged upstream from the moveable body, the seat being arranged at a downstream opening of a hollow seat extension section having an upstream opening, and wherein the moveable body further comprises a protrusion having a solid body that extends through the seat and past said upstream opening of said hollow seat extension section, the protrusion being dimensioned to leave a gap between its lateral surface and an inside of said hollow seat extension section, wherein the protrusion has an upstream end configured to mechanically interact with an upstream end of said hollow seat extension section to delimit movement of the moveable body in a downstream direction.

2 . The inhalation device according to claim 1 , wherein the check valve is fluidically arranged between the reservoir and the pumping unit.

3 . The inhalation device according to claim 1 , wherein the check valve is fluidically arranged between the pumping unit and the nozzle.

4 . The inhalation device according to claim 1 , wherein the upstream end of the protrusion of the check valve comprises at least one flexible structure which is configured to be elastically deformable such as to fit, in a deformed state, within the hollow seat extension section, and to permanently unfold when arranged past said hollow seat extension section such that said upstream end of the protrusion extends laterally beyond a width of the upstream opening of the hollow seat extension section.

5 . The inhalation device according to claim 1 , wherein a ring-like structure is attached to the upstream end of the protrusion of the check valve which increases an overall lateral size of the upstream end of the protrusion such that it is larger than the width of the upstream opening of the hollow seat extension section.

6 . The inhalation device according to claim 1 , wherein the upstream end of the protrusion of the check valve is configured to provide a magnetic force which counteracts a magnet arranged inside the hollow seat extension section and/or at the upstream end thereof, such that the balance of magnetic forces limits the movement of the body.

7 . The inhalation device according to claim 1 , wherein a diameter of the valve body is 1 mm±0.3 mm, and/or a length of the protrusion is 0.5 mm±0.4 mm, and/or the gap has a width between 50 μm and 1000 μm, and/or an upstream end of the protrusion laterally surpasses the upstream opening of the hollow seat extension section by at least 0.5 mm.

8 . The inhalation device according to claim 1 , wherein the pumping unit comprises a stationary or fixed piston and a moveable cylindrical part.

9 . The inhalation device according to claim 1 , wherein a dead volume of the check valve is lower than 500 μm 3 .

10 . The inhalation device according to claim 1 , wherein a dead volume of the check valve is selected within the range of from about 0.001 μm 3 to about 100 μm 3 .

11 . The inhalation device according to claim 1 , wherein a flow rate of the medically active liquid through the opened check valve is selected within a range of from about 1 μl/sec to about 100 μl/sec.

12 . The inhalation device according to claim 1 , wherein the check valve allows an opening and closing time of up to 100 msec.

13 . The inhalation device according to claim 1 , wherein the medically active liquid is a pharmaceutical composition comprising at least one inhalable active ingredient selected from the group consisting of long-acting muscarinic antagonists (LAMA), long-acting beta antagonists (LABA) and inhalable glucocorticosteroids (ICS).

14 . A method of treating a subject suffering from a respiratory disease, disorder, or condition; or for preventing a respiratory disease, disorder, or condition in the subject, the method comprising a step of administering a pharmaceutical composition in nebulized form to said subject using an inhalation device according to claim 1 .

15 . The method of claim 14 , wherein the respiratory disease, disorder, or condition is a lung disease, disorder, or condition.

16 . The method of claim 14 , wherein the respiratory disease, disorder, or condition is asthma and/or chronic obstructive pulmonary disease (COPD).

17 . The inhalation device according to claim 1 , wherein the upstream end of the protrusion is smaller than the moveable body.

18 . The inhalation device according to claim 1 , wherein the upstream end of the protrusion has a smaller cross-sectional area than the moveable body.

19 . The inhalation device according to claim 1 , wherein the upstream end of the protrusion has a smaller diameter than the moveable body.

20 . The inhalation device according to claim 1 , wherein a rod-like structure is perpendicularly attached to the upstream end of the protrusion of the check valve which increases an overall lateral size of the upstream end of the protrusion such that it is larger than a width of the upstream opening of the hollow seat extension section.

Assignments (2)
CHANGE OF NAME Recorded Oct 3, 2024
From: SOFTHALE NV
To: INVOX BELGIUM NV
Reel/Frame 069105/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 20, 2021
From: BARTELS, FRANK; RAWERT, JUERGEN
To: SOFTHALE NV
Reel/Frame 058426/0725 →
Priority Claims (1)
EP 19169154 · Apr 15, 2019 · regional
Continuity (2)
Provisional Application 62833977 · Apr 15, 2019
Related Publication 20220143328A1 · May 12, 2022
References Cited (35)
US 5152434A · Birmelin · 1992 [cited by applicant]
US 5161574A · Chacin · 1992 [cited by examiner]
US 5349984A · Weinheimer et al. · 1994 [cited by applicant]
US 5429275A · Katz · 1995 [cited by applicant]
US 5894960A · Rodden, Jr. · 1999 [cited by applicant]
US 5964416A · Jaeger · 1999 [cited by examiner]
US 6189739B1 · von Schuckmann · 2001 [cited by examiner]
US 9757750B2 · Holakovsky · 2017 [cited by examiner]
US 11035066B2 · Nam · 2021 [cited by examiner]
US 20020166876A1 · Masuda · 2002 [cited by applicant]
US 20040068222A1 · Brian · 2004 [cited by examiner]
US 20040194828A1 · Landhuis · 2004 [cited by applicant]
US 20080017256A1 · Thomas · 2008 [cited by examiner]
US 20110290242A1 · Bach · 2011 [cited by examiner]
US 20120138049A1 · Wachtel · 2012 [cited by applicant]
US 20140182716A1 · Yamada et al. · 2014 [cited by applicant]
US 20200324306A1 · Bilton · 2020 [cited by examiner]
CN 1534203A · 2004 [cited by applicant]
CN 101255927A · 2008 [cited by applicant]
CN 103899382A · 2014 [cited by applicant]
EP 0627230B1 · 2000 [cited by applicant]
JP 2002066401A · 2022 [cited by applicant]
KR 100615036B1 · 2006 [cited by applicant]
KR 101486012B1 · 2015 [cited by applicant]
WO 2008011240A2 · 2008 [cited by applicant]
WO 2010133294A2 · 2010 [cited by applicant]
WO 2015191478A1 · 2015 [cited by applicant]
WO 2018189424A1 · 2018 [cited by applicant]
WO 2018197730A1 · 2018 [cited by applicant]
Erb et al. “Antiasthmatic Agents”, https://onlinelibrary.wiley.com/doi/full/10.1002/14356007.a02_453.pub2?a02_453-eo-2013= accessed on Oct. 2024 (Year: 2010). [cited by examiner]
Kim et al. “Overlap between Asthma and COPD”, https://pmc.ncbi.nlm.nih.gov/articles/PMC2946698/#:˜:text=There%20is%20a%20marked%20increase,lavage%20fluid%20and%20induced%20sputum.&text=Given%20that%20asthma%20and%20COPD… [cited by examiner]
Written Opinion of the International Searching Authority of International Patent Application No. PCT/EP2020/060403, Jun. 12, 2020, 7. [cited by applicant]
EN translation of the Search report of CN113677386 dated May 29, 2024. [cited by applicant]
EP examination report of Mar. 7, 2024. [cited by applicant]
TW Office action of Aug. 10, 2023. [cited by applicant]